[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100619887":3},{"organization":4,"armGroups":7,"interventions":22,"overallOfficials":41,"centralContacts":46,"locations":57,"responsibleParty":75,"collaborators":28,"id":79,"slug":80,"hasResults":81,"nctId":82,"briefTitle":83,"officialTitle":84,"acronym":85,"eligibilityCriteria":86,"healthyVolunteers":81,"sex":87,"minAge":88,"maxAge":89,"enrollmentInfo":90,"targetDuration":28,"studyType":93,"phases":94,"briefSummary":96,"conditions":97,"keywords":100,"overallStatus":60,"whyStopped":28,"lastUpdateSubmitDate":104,"lastUpdatePostDateStruct":105,"startDateStruct":108,"completionDateStruct":110,"leadSponsor":112,"locationsCount":113},{"fullName":5,"class":6},"Ente Ospedaliero Cantonale, Bellinzona","OTHER",[8,15],{"label":9,"type":10,"description":11,"interventionNames":12},"Pudendal block","ACTIVE_COMPARATOR","Patients in the control group will receive an ultrasound-guided bilateral pudendal nerve block with 20 mL of 0.75% ropivacaine and a sacral ESP block with 20 mL of normal saline. Blinding is ensured by the double block procedure",[13,14],"Procedure: Pudendal block AL","Procedure: Sacral ESP block Sham",{"label":16,"type":17,"description":18,"interventionNames":19},"Sacral ESP block","EXPERIMENTAL","Patients in the intervention group will receive an ultrasound-guided sacral ESP block with 20 mL of 0.75% ropivacaine and a bilateral pudendal nerve block with 20 mL of normal saline.",[20,21],"Procedure: Sacral ESP block AL","Procedure: Pudendal block Sham",[23,29,33,37],{"type":24,"name":25,"description":26,"armGroupLabels":27,"otherNames":28},"PROCEDURE","Pudendal block AL","Patients in the control group will receive an ultrasound-guided bilateral pudendal nerve block with 20 mL of 0.75% ropivacaine",[9],null,{"type":24,"name":30,"description":31,"armGroupLabels":32,"otherNames":28},"Sacral ESP block AL","Patients in the intervention group will receive an ultrasound-guided sacral ESP block with 20 mL of 0.75% ropivacaine",[16],{"type":24,"name":34,"description":35,"armGroupLabels":36,"otherNames":28},"Sacral ESP block Sham","Patients in the control group will receive a sacral ESP block with 20 mL of normal saline.",[9],{"type":24,"name":38,"description":39,"armGroupLabels":40,"otherNames":28},"Pudendal block Sham","Patients will receive a bilateral pudendal nerve block with 20 mL of normal saline.",[16],[42],{"name":43,"affiliation":44,"role":45},"Andrea Saporito, Prof. Dr. Med.","Department of Anesthesiology, Ospedale San Giovanni, Ente Ospedaliero Cantonale, Bellinzona, Switzerland","STUDY_CHAIR",[47,53],{"name":48,"role":49,"phone":50,"phoneExt":51,"email":52},"Roberto Dossi, Dr. Med.","CONTACT","0041 (0)91 811","9341","Roberto.Dossi@eoc.ch",{"name":54,"role":49,"phone":50,"phoneExt":55,"email":56},"Alessandra Lauretta, Dr. Med.","8182","Alessandra.Lauretta@eoc.ch",[58],{"facility":59,"status":60,"city":61,"state":28,"zip":62,"country":63,"countryCode":64,"cosmosGeoPoint":65,"geoPoint":70,"contacts":71},"Ospedale Regionale Bellinzona e Valli (ORBV) CH-6500 Bellinzona Switzerland","RECRUITING","Bellinzona","6500","Switzerland","CH",{"type":66,"coordinates":67},"Point",[68,69],9.01703,46.19278,{"lat":69,"lon":68},[72,74],{"name":48,"role":49,"phone":73,"phoneExt":51,"email":52},"0041 (0) 91 811",{"name":54,"role":49,"phone":50,"phoneExt":55,"email":56},{"type":76,"investigatorFullName":77,"investigatorTitle":78,"investigatorAffiliation":5,"oldNameTitle":28,"oldOrganization":28},"SPONSOR_INVESTIGATOR","Andrea Saporito","Prof. Dr. Med.","100619887","pushes-pudendal-block-versus-sacral-esp-hemorrhoidectomy-study-100619887",false,"NCT07350460","PUSHES (Pudendal Block Versus Sacral ESP Hemorrhoidectomy Study)","A Randomized, Double-Blind Trial Comparing Pudendal Block Versus Sacral ESP for Ambulatory Hemorrhoidectomy","PUSHES","Inclusion Criteria:\n\n* Adults (≥18 years old) scheduled for elective excisional hemorrhoidectomy;\n* Ability to understand the nature of the study and provide written informed consent;\n* American Society of Anesthesiologists (ASA) physical status I-III;\n* Ability to comply with study procedures and postoperative evaluations.\n\nExclusion Criteria:\n\n* Pregnancy;\n* Body weight under 50 kg due to the potential risk of local anaesthetic systemic toxicity (LAST);\n* BMI \\> 40; Known allergy or contraindication to local anaesthetics (e.g., ropivacaine, prilocaine);\n* Severe coagulation disorders or current anticoagulant therapy contraindicating spinal or peripheral deep nerve blocks (like pudendal block, because Sacral ESP is considered a superficial block);\n* Infection at the puncture site;\n* Neurological disorders affecting the sacral or pudendal nerve pathways;\n* Severe psychiatric conditions impairing study participation;\n* Language barriers","ALL","18 Years","80 Years",{"count":91,"type":92},64,"ESTIMATED","INTERVENTIONAL",[95],"NA","The goal of this clinical trial is to learn if the sacral erector spinae plane block can provide equal or better pain control than the pudendal nerve block in adults undergoing hemorrhoid surgery. The main question is: Which block offers more effective analgesia and faster recovery?",[98,99],"Hemorrhoids","Hemorrhoids Third Degree",[98,101,102,103],"Hemorrhoidectomy","Postoperative Pain","Pain Measurement","2026-03-16",{"date":106,"type":107},"2026-03-18","ACTUAL",{"date":109,"type":107},"2026-01-05",{"date":111,"type":92},"2027-09-30",{"name":77,"class":6},1]